Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement
26 Julho 2023 - 5:15PM
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V.
(NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that
the companies have agreed to settle their patent dispute pending in
the U.S. District Court of Delaware pursuant to a global settlement
and patent cross-licensing agreement relating to digital PCR
technology.
The settlement provides for a cross-licensing
agreement between Bio-Rad and QIAGEN granting each company mutual
rights to their respective digital PCR technologies.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb)
is a leader in developing, manufacturing, and marketing a broad
range of products for the life science research and clinical
diagnostics markets. Based in Hercules, California, Bio-Rad
operates a global network of research, development, manufacturing,
and sales operations with over 8,000 employees and $2.8 billion in
revenues in 2022. Our customers include universities, research
institutions, hospitals, food safety and environmental quality
laboratories, and biopharmaceutical companies. Together, we develop
innovative, high-quality products that advance science and save
lives. To learn more, visit bio-rad.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. QIAGEN
provides solutions to more than 500,000 customers around the world
in Molecular Diagnostics (human healthcare) and Life Sciences
(academia, pharma R&D and industrial applications, primarily
forensics). In 2022, QIAGEN had net sales of more than $2.1 billion
and over 6,200 employees. Further information can be found at
http://www.qiagen.com.
BIO-RAD is a trademark of Bio-Rad Laboratories,
Inc. in certain jurisdictions.
QIAGEN is a trademark of QIAGEN N.V. in certain
jurisdictions.
Source: QIAGEN N.V.Category: Corporate
Edward Chung
Bio-Rad Laboratories, Inc.
510-741-6104
ir@bio-rad.com
Anna Gralinska
Bio-Rad Laboratories, Inc.
510-741-6643
cc@bio-rad.com
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024